

IRRAS Q4 - Continues to lay the building blocks

Redeye has a relatively neutral stance on IRRAS' Q4 report, with sales coming in under and costs above our forecasts. We highlight the commercial partnership with Medtronic and argue that it underpins the potential of IRRFlow. The biggest concern in the short term is the company's cash position, and we expect an equity issue towards the end of H1 2023e.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

IRRAS Q4 - Continues to lay the building blocks